Quick ReadPlain-language overview · read this first
Samsung Biologics is the world's largest biologics “foundry.” The report's stance is Hold: the business is excellent, but the current price is not cheap enough, so it is better to wait for a more attractive entry point.
First, what does it mainly do? It does not develop its own drugs. Instead, it manufactures biologics for major pharmaceutical companies such as Pfizer, Roche, and Eli Lilly. This is a “picks and shovels” business built on scale, capacity, and quality. This year, it also made a major move: it spun off the biosimilar business that could have conflicted with clients, becoming a clean pure-play manufacturer that does not compete with customers. That makes major pharmaceutical companies more comfortable handing it orders.
How profitable is this business? For every 100 won of sales, about 45 won is left after costs (rare for a contract manufacturer), and revenue is still rising at about 30% per year. Its core strength is having the world's largest capacity. Once production is validated and running in its facilities, customers find it hard to switch to another supplier.
So why only Hold? The problem is price. For the same type of business, it is the most expensive name among peers. The market is willing to pay this high price because it is betting that a new U.S. rule will push orders away from Chinese manufacturers and toward Samsung Biologics. But that benefit remains only an expectation for now; the orders have not truly shifted, and the earliest timing is 2027. Even the local brokerage that is most positive on it recently cut its target price from KRW 2.10 million to KRW 1.80 million. On top of that, it must keep spending heavily on new plants, and its customer base is concentrated among a small number of large clients, both of which warrant caution.
The share price has already fallen by about 30% from its high at the start of the year, removing part of the expensive froth, but it still cannot be called cheap. The report's view is: wait until it falls below roughly KRW 1.15 million, then consider it with a better cushion; at that point, the stance could be raised to Cautious Buy. Until then, hold the shares and closely watch whether orders actually transfer.
The above is only a plain-English explanation of this report and is not investment advice. The stock market involves risk; invest with caution.
LeadSamsung Biologics is the world's largest biologics CDMO, a contract development and manufacturing platform that became a pure-play CDMO after spinning off Samsung Bioepis in November 2025. Its core case rests on world-leading capacity of roughly 780,000 liters, operating margin near 45%, revenue growth above 30%, relationships with 17 of the world's top 20 pharmaceutical companies, and a $21.4B backlog, but the valuation already prices in capacity leadership and BIOSECURE upside that has not yet been proven in orders. Report rating Hold: a top-tier compounder deserves a premium, but at the current price the margin of safety is thin.
Prices in the article are as of publication; see the valuation band above for the live price.
Research base date: 2026-06-05 | Listing venue: Korea Exchange KOSPI (ticker 207940) | Currency: KRW | Investment lens: long-term fundamentals plus valuation discipline, covering both 12 months and 3-5 years | Risk preference: balanced. Important basis note: the company completed its spin-off in November 2025, and 207940 is now a pure-play CDMO entity. The biosimilar business Samsung Bioepis has been separated into the independently listed Samsung Epis Holdings. All financials and valuation work in this report use the pure-play CDMO basis. Data for 2024 and earlier may differ from the historical consolidated basis that included Bioepis when restated on a pure-play CDMO basis; each such instance is marked in the text. This report is research analysis based on public information and does not constitute investment advice.
1. Research Summary: A Global Outsourcing King That Has Just Shed Its Burden, Now Trading Near Its Richest Valuation Band
Samsung Biologics can be described in one sentence: it is the biologics manufacturing plant for large pharmaceutical companies, and the world's largest biologics CDMO, or contract development and manufacturing organization. Giants such as Pfizer, BMS, Roche, Eli Lilly, AstraZeneca, GSK, Novartis, and Moderna outsource the development and commercial manufacturing of biologics such as monoclonal antibodies, bispecific antibodies, ADCs, and mRNA products to Samsung Biologics. It does not develop its own original drugs, which makes it fundamentally different from a classic pharmaceutical company. It earns money as a "picks-and-shovels" business built on scale, capacity, quality, and delivery.
What major event happened recently? In November 2025, Samsung Biologics completed a critical spin-off restructuring: it separated its biosimilar subsidiary Samsung Bioepis into a newly listed independent holding company, Samsung Epis Holdings, while Samsung Biologics itself became a pure-play CDMO. This step matters greatly. It removed a structural conflict that had long weighed on valuation: large pharmaceutical customers had been reluctant to hand proprietary biologics data to a manufacturer that also owned a biosimilar business and could compete with them. After the spin-off, the listed entity 207940 contains only the CDMO business. The conflict of interest has been removed, and the valuation lens has shifted from a hybrid of "order-driven CDMO plus R&D-driven Bioepis" to a clean outsourcing business.
How strong is the business? It is close to the ceiling of the category: the world's largest capacity, with Songdo Plants 1-5 totaling roughly 785,000 liters and, including the Rockville plant in the United States, about 845,000 liters, making it the world's largest single biologics manufacturing site; 2025 pure-play CDMO revenue of ₩4.56 trillion, about 30% growth, operating profit of ₩2.07 trillion, and operating margin of roughly 45%; cumulative backlog above $21.4 billion and relationships with 17 of the world's top 20 pharmaceutical companies. A contract manufacturer with 45% operating margin that is still growing at 30% is rare in manufacturing.
What narrative is the market trading now? In one line: "BIOSECURE upside plus capacity dominance." The U.S. BIOSECURE Act restricts federally funded institutions from using Chinese CDMOs, with the WuXi companies at the center of market attention. Investors expect a large amount of business to shift from China to suppliers such as Samsung Biologics, which combine a "neutral country" profile with large capacity. This is the core source of its valuation premium, and the degree to which this thesis actually materializes is one of the key issues this report examines.
Where does the stock stand now? Fundamentals are on the right side of "spin-off burden removal plus capacity ramp plus high growth." Valuation is at a relatively elevated level versus history and peers, with EV/EBITDA around 22x, the richest in the group. The share price has pulled back about 33% from its 52-week high of ₩1,987,000 in January 2026 to about ₩1,336,000 currently. This is a classic combination of top-tier business, rich price, and unproven core catalyst. Asset quality is hard to dispute; the issue is that the price already capitalizes both capacity dominance and the still-unrealized BIOSECURE benefit.
What is the most important bull-bear debate now? It is not business quality. Both sides acknowledge Samsung Biologics is one of the world's best CDMOs. The debate is about two questions: how much BIOSECURE benefit will actually arrive, and when; and whether the current valuation is expensive, meaning whether 45% gross-margin quality and 30% growth deserve 22x EV/EBITDA, or whether the market has already overpaid.
Qualitative label: global top-tier CDMO plus post-spin purity, high quality and high growth, but fully valued. Basis: the business quality, including world-leading capacity, operating margin near 45%, 30%+ growth, relationships with top global pharmaceutical companies, and removal of conflicts of interest after the spin-off, supports the "global top-tier CDMO" label. But the peer-high valuation multiple, the still-unproven order impact from the key BIOSECURE catalyst, and a rising heavy-asset capex cycle prevent it from being "cheap enough to buy." The specific rating is left to Section 12, where it follows naturally from the facts above.
2. Vertical History: From a Samsung Group Wager to the World's Largest Biologics Manufacturer
2.1 Origin: In 2011, Samsung Group Bet That "Biologics Also Needed a Foxconn"
Samsung Biologics was established by Samsung Group in Songdo, Incheon, in April 2011. Samsung's judgment was very Samsung-like: just as it had done in semiconductors and displays, biologics, a high-barrier and heavily regulated product category, would ultimately need a very large-scale, very high-quality outsourcing platform, much like Foxconn in electronics. Construction of Plant 1, with 30,000 liters of capacity, began in May 2011, and the plant reached cGMP-standard commercial operation in 2013. In the same year, Samsung established Samsung Bioepis with U.S.-based Biogen to develop biosimilars. That business line was spun off 14 years later, as discussed below.
2.2 Capacity Snowball: From 30,000 Liters to Global Number One
The history of Samsung Biologics is essentially a history of capacity expansion: Plant 2, with 155,000 liters in 2016; Plant 3, with 180,000 liters in 2018 and the world's largest single plant at the time; Plant 4, with 240,000 liters in 2023, again setting the global single-plant record; and Plant 5, with 180,000 liters, operational in April 2025. By 2025, the Songdo campus totaled roughly 785,000 liters, making it the world's largest single biologics manufacturing site. Bio Campus II, now under construction, is planned to lift total capacity to about 1.32 million liters by 2032, plus the U.S. Rockville, Maryland plant acquired for $353 million in 2026, adding 60,000 liters. Capacity dominance is its hardest moat. Biologics production lines require long qualification cycles and customer switching costs are extremely high. Whoever has the largest, qualified, and immediately deliverable capacity wins orders.
2.3 Capital Markets and an Unavoidable Accounting Legacy Case
In November 2016, Samsung Biologics listed on KOSPI at an offering price of ₩136,000, raising roughly ₩2.2 trillion, or about $2.0 billion, in Korea's third-largest IPO in history. In 2022, it bought out Biogen's entire stake in Bioepis for $2.3 billion, achieving 100% ownership.
But there is an unavoidable controversy in its history. In 2018, Korea's Securities and Futures Commission, or SFC, found that Samsung Biologics had intentionally violated accounting standards before its 2016 IPO to raise the valuation of Bioepis, involving more than ₩4 trillion; the company was fined, briefly suspended, and faced a delisting review. At the judicial level, however, the outcome was acquittal: Lee Jae-yong was acquitted in the first-instance ruling in 2024, and in 2025 Korea's Supreme Court upheld that the accounting treatment was lawful. The administrative penalty and criminal judicial finding pointed in opposite directions, and the case ultimately ended with judicial acquittal. This history remains relevant background for understanding the "Korea discount" governance narrative, but the legal process has concluded.
2.4 The 2025 Burden Removal: Spinning Off Bioepis to Become a Pure-Play CDMO
This is the single most important step for understanding Samsung Biologics today. Announced in May 2025, approved at an extraordinary shareholder meeting on October 17 with 99.9% support, completed in November, and followed by the separate relisting of both companies on KOSPI on November 24, the structure was a Korean-style personal split, or 인적분할. 207940 remained the surviving listed CDMO entity with the same ticker, while Bioepis was placed into the newly formed pure holding company Samsung Epis Holdings. Original shareholders received roughly 0.65 share of Samsung Biologics CDMO plus 0.35 share of Samsung Epis Holdings for each original share. The CFO's own words explained the motivation: "despite our significant efforts, it was clear that we could not fully eliminate customers' concerns through governance mechanisms alone". In other words, customers were uncomfortable with a manufacturer that also made biosimilars and could compete with them. After the spin-off, 207940 became a pure-play CDMO and the conflict of interest was removed. This is also the dividing line for its valuation and reporting basis from 2025 onward.
3. Vertical Financial Review: High Growth Plus High Profitability, but Two Reporting Bases Must Be Kept Separate
The first task in reading Samsung Biologics' financials is to separate the reporting bases. Otherwise the conclusion will be completely wrong.
Consolidated basis including Bioepis (the main disclosure basis for 2024 and earlier): 2024 consolidated revenue of ₩4.547 trillion and operating profit of ₩1.320 trillion.
Pure-play CDMO basis (from 2025 onward, excluding the spun-off Bioepis; the company has restated history): 2024 revenue restated to ₩3.497 trillion.
| Fiscal year (pure-play CDMO basis) | Revenue (₩ billion) | Operating profit (₩ billion) | Operating margin |
|---|---|---|---|
| 2020 | 1,165 | 293 | 25.2% |
| 2021 | 1,568 | 537 | 34.3% |
| 2022 | 2,437 | 969 | 39.8% |
| 2023 | 2,939 | 1,206 | 41.0% |
| 2024 (restated) | 3,497 | 1,321 | 37.8% |
| 2025 | 4,557 | 2,069 | 45.4% |
Sources: company IR Financial Snapshot, 2025 annual results press release.
First, the growth is real and sustained, but do not be misled by the basis. A common misreading is to compare "2025 revenue of ₩4,557 billion" with "2024 including Bioepis of ₩4,547 billion" and conclude there was no growth. That mixes reporting bases. On the same pure-play CDMO basis, 2025 revenue grew 30.3% from the restated 2024 revenue of ₩3,497 billion, and operating profit grew 56.6%. This is a rare contract manufacturer with sustained high growth in both revenue and profit.
Second, profitability is unusually strong for outsourcing, and stronger after the spin-off. On the pure-play CDMO basis, operating margin rose from 25% in 2020 to about 45% in 2025. There are two reasons. One is scale economies from capacity plus a higher mix of advanced modalities such as bispecific antibodies and ADCs. The other is the separation of Bioepis. Biosimilars are R&D-driven and have margins only a little above 20%; after the separation, the 40%+ margin of pure contract manufacturing is no longer diluted.
Third, 2026 Q1 continued the high growth. In Q1 2026, revenue was ₩1.257 trillion, up 25.8%; operating profit was ₩580.8 billion, up 35%; net income was ₩469.2 billion, up 41.6%; operating margin exceeded 46%; Plants 1-4 ran at full capacity; and cumulative backlog passed $21.4 billion. The company's full-year 2026 guidance is 15-20% revenue growth, excluding contribution from the planned U.S. capacity acquisition.
Fourth, this is a heavy-asset business. CDMOs buy growth by continually investing in plants: 2025 capex was about ₩1.98 trillion, and total investment in Bio Campus II is about ₩7 trillion. High capex is the price of growth and also a risk. If demand slows, utilization and returns on massive capacity will come under pressure, as discussed in Section 10. On the balance sheet, total assets fell from ₩15.4 trillion in 2024, including Bioepis, to about ₩11.1 trillion in 2025 after the spin-off. This "balance sheet shrinkage" is purely a result of the spin-off, not operating deterioration.
4. Share Price and Valuation History: From Emperor Stock to Spin-Off Re-Rating, Then a 33% Pullback
Samsung Biologics has long been an "emperor stock" in Korea, meaning a high-priced stock with a per-share price above one million won:
The 2016 IPO price was ₩136,000. The current price of about ₩1,336,000 is roughly 10x higher. Note that the company has never split its stock; par value has remained ₩2,500, so the IPO price and current price are directly comparable.
In August 2021 during COVID, it first crossed ₩1,000,000, with a peak around ₩1,034,746, driven by expectations around Moderna COVID vaccine manufacturing and earnings.
After the November 2025 spin-off and relisting, the stock surged. On January 12, 2026, it touched a 52-week high of ₩1,987,000, as brokers raised target prices and re-rated it as a pure-play CDMO.
It then corrected about 33% to the current level near ₩1,336,000, with a 52-week range of about ₩1,300,000-1,987,000.
Key point: the current price has pulled back by about one-third from the 52-week high, so some euphoria has faded. But absolute valuation remains high versus history and peers, as discussed in Section 9. Reminder: the ₩1.03M level in 2021 was on the pre-spin basis, while the ₩1.99M level in early 2026 was on the post-spin pure-play CDMO basis. They should not be compared mechanically as "which was higher."
5. Business Model and Moat: Capacity Dominance, Quality, Customer Stickiness, and Greater Purity After the Spin-Off
Samsung Biologics has three layers of moat, all of them wide:
5.1 Capacity Dominance, the Hardest Moat
It has the world's largest single-site biologics manufacturing capacity, with about 785,000 liters in Songdo plus 60,000 liters in the United States, and it continues to expand through Plant 5/6 and Bio Campus II. In biologics outsourcing, the availability of large, qualified, immediately usable capacity directly determines whether a company can win large orders. Large pharmaceutical companies want delivery certainty. Samsung's scale is its hardest advantage to replicate.
5.2 Quality and Customer Stickiness
Batch success rate is about 99%, versus an industry average of 90-95%; cumulative global regulatory approvals are about 340; the company works with 17 of the top 20 global pharmaceutical companies; and cumulative CMO contracts exceed $21.4 billion. Once biologics manufacturing is validated at a plant, switching facilities requires new process validation and regulatory filings, with very high costs. Customer stickiness is strong, and long-term contracts are common. Samsung is also filling in advanced modalities, including bispecific antibodies, a dedicated ADC facility launched in March 2025, CGT, and AAV, keeping pace with the industry's migration toward complex molecules.
5.3 The Post-Spin "Neutrality" Premium
This is the new moat added in 2025. After spinning off Bioepis, Samsung Biologics became a pure manufacturer that does not compete with customers. For large pharmaceutical companies that fear both data leakage and biosimilar competition, a "clean neutral manufacturer" is more trustworthy. This is the commercial logic of the spin-off and it strengthens Samsung's appeal versus competitors that still have proprietary drug pipelines.
5.4 But Be Honest: It Is Still a Picks-and-Shovels Business, and Its Fate Depends on Customer Pipelines and Outsourcing Decisions
Despite the wide moat, Samsung Biologics is still a B2B contract manufacturer. Its growth depends on whether large pharmaceutical companies' biologics pipelines expand, whether outsourcing rates rise, and whether orders concentrate with Samsung. It does not control end-drug pricing power, and customer concentration is high. The company does not disclose exact shares; analytical sources estimate that the top five customers often account for more than half of revenue, while a single large customer can reach 20-30% in some periods. This means its valuation should not enjoy the monopoly-style premium of an originator pharmaceutical company.
6. Industry and BIOSECURE: The Tailwind Is Real, but the Benefit Arrives Slowly
6.1 Biologics CDMO Industry: A Long Runway, but Growth Estimates Vary Widely
Biologics CDMO is the outsourcing market for development and manufacturing of large molecules such as monoclonal antibodies, bispecific antibodies, ADCs, vaccines, and cell and gene therapies. The market size in 2025 is about $23-26 billion, but institutional estimates of long-term growth vary widely, with CAGR ranging from 7% to 15%. Any citation must state its basis; one number should not be treated as industry consensus. The drivers are clear: biologics pipeline expansion, higher outsourcing rates at large pharmaceutical companies, biosimilar volume growth, and penetration of new modalities.
6.2 Weight-Loss Drug Benefit: A Common Misreading
The market often says broadly that "Samsung benefits from weight-loss drugs." This needs correction: Samsung Biologics is centered on monoclonal antibodies, using mammalian cell expression, while GLP-1 weight-loss drugs are peptides, made through chemical synthesis or microbial routes, with different production lines. GLP-1 volume growth directly benefits peptide CDMOs, not Samsung's core lines by default. Samsung only began actively moving into peptides in 2026, by evaluating the acquisition of a U.S. weight-loss drug plant and setting up a peptide platform subsidiary within the Epis system. So weight-loss drugs are an incremental option Samsung is actively pursuing, not a current core-business beneficiary. Do not overstate it.
6.3 BIOSECURE Act: Enacted, but Benefit Is Low-Visibility and Delayed
This is the core narrative behind Samsung Biologics' valuation premium, and "enacted" must be separated from "realized."
The act has indeed become law: On December 18, 2025, BIOSECURE was signed into law as part of the FY2026 National Defense Authorization Act, or NDAA. It restricts contracts and grants by U.S. federal agencies for services provided by "biotechnology companies of concern."
But the enacted version no longer names specific companies: it instead uses the Department of Defense 1260H list process, and WuXi AppTec and WuXi Biologics have not yet been added to 1260H.
Implementation still has to wait: OMB must publish the full list by December 18, 2026, and the Federal Acquisition Regulation, or FAR, must then be amended before restrictions take effect. The benefit can realistically start no earlier than 2027.
The most important counterevidence is that the benefit has not yet materialized: WuXi Biologics still reported record 2025 results, with revenue up 16.7%, gross margin rising to 46%, and backlog of $23.7 billion. In other words, "orders shifting from China to Samsung" had not truly appeared in the 2025 data. Samsung's large 2025 contracts, $1.4 billion in Europe and $1.3 billion in the United States, are not linked to disclosed customers because of confidentiality agreements, so they cannot directly prove a "WuXi order shift".
Judgment: BIOSECURE is an established medium- to long-term positive for Samsung, but the current market treatment is mainly expectation pricing, with low realization and a delay until after 2027. Treating it as already contributing orders would be an overstatement.
7. Horizontal Peer Comparison: Number One in Capacity, Highest Margin, Fastest Growth, and Also the Most Expensive
Global biologics CDMO first-tier comparison, with market capitalization and valuation as of 2026-06-05; KRW/USD exchange rates have been volatile recently, so USD market caps are approximate:
| Company | Market cap (approx.) | PE-TTM | EV/EBITDA | Operating margin | Capacity/revenue position | BIOSECURE |
|---|---|---|---|---|---|---|
| Samsung Biologics 207940.KO | ₩62 trillion (~$40B+) | ~47-51x | ~22x | ~45-46% | Global capacity leader | Net beneficiary |
| Lonza (LONN.SW) | ~$43B | ~38x* | ~18x | Core EBITDA 31.6% | Revenue leader (~$8B) | Beneficiary |
| WuXi Biologics (2269.HK) | ~$17B | ~25x | ~14x | ~30% | Among leaders in capacity/revenue | Impaired (>60% of revenue from the U.S.) |
| Fujifilm (4901.T) | ~$26B (group) | ~14x (group) | N/A | 10% (group) | Bio CDMO is only a small part of group | Beneficiary |
| Boehringer Ingelheim | Unlisted | N/A | N/A | N/A | First tier | N/A |
| Catalent | Privatized by Novo (2024) | N/A | N/A | N/A | Delisted | N/A |
Sources: stockanalysis.com pages for each company, company IR. *Lonza PE-TTM is distorted by one-off goodwill impairment; EV/EBITDA of 18x is cleaner. Fujifilm is a diversified group, so group multiples are not directly comparable with pure-play CDMOs and are only a qualitative reference.
The horizontal conclusion is clear: Samsung Biologics is the strongest in this group on capacity, gross margin, and growth, but it is also the most expensive. Its EV/EBITDA is about 22x, materially above Lonza at 18x and WuXi Biologics at 14x. WuXi Biologics is especially interesting: its growth and gross margin are still solid, but BIOSECURE geopolitical discounting has made it the cheapest in the group at 14x EV/EBITDA. Samsung and WuXi are two sides of the same valuation transfer. The premium in Samsung buys "neutral country plus largest capacity plus 45% margin plus BIOSECURE beneficiary." But the premium is already substantial, and further upside requires those expectations to continue materializing.
8. Current Fundamentals and Bull-Bear Case: A Good Business Is Already Fully Priced
8.1 Bull Case, Valid but Largely Reflected in Price
World-leading capacity and continuing expansion: 785,000 liters in Songdo plus Plant 5/6, Bio Campus II reaching 1.32 million liters by 2032, and U.S. Rockville.
High growth, high profitability, and acceleration: 2025 pure-play CDMO revenue up 30%, operating profit up 56.6%, margin around 45%; Q1 2026 continued the trend.
Spin-off removes conflict of interest and adds neutrality premium: as a pure-play CDMO, it is more trusted by large pharmaceutical companies and the valuation basis is clearer.
Top-tier backlog and customer quality: cumulative orders above $21.4 billion and relationships with 17 of the top 20 pharmaceutical companies.
Net BIOSECURE beneficiary: relative to the WuXi companies, it is a "neutral country with large capacity" receiver.
8.2 Bear Case, More Important to Respect
Most expensive valuation: EV/EBITDA of about 22x is the highest among peers, forward PE is about 30-35x, and PB is about 6-8x depending on basis. The premium is already full.
BIOSECURE benefit is priced in but not realized: WuXi still posted record results in 2025, has not been named, and implementation begins no earlier than 2027, as discussed in Section 6.
Broker cooling has begun: In May 2026, Samsung Securities cut its target price from ₩2,100,000 to ₩1,800,000, citing unreflected risk from restructuring in U.S. CDMO order patterns and structurally rising labor costs, and saying substantive order momentum may not recover until after the second half of 2026.
Heavy-asset capex cycle plus customer concentration: Bio Campus II requires ₩7 trillion of investment, pressuring free cash flow; the top five customers account for more than half of revenue.
KRW FX and governance discount: revenue is denominated in USD while reports are in KRW, so won volatility has direct impact; Korea's governance discount and a free float of only about 25% also matter.
8.3 An Honest Reminder: The Stock Has De-Rated, but It Is Not Cheap
The current price is down about 33% from the 52-week high, which means some euphoria has faded and the entry point has improved. But EV/EBITDA of 22x and forward PE of 30-35x remain high for a heavy-asset contract manufacturer whose demand is influenced by biotech funding cycles. It deserves a premium because the quality is genuinely top-tier, but the current price lacks a thick margin of safety.
9. Valuation: Top-Tier Quality Supports a Premium, but There Is Little Margin of Safety at the Current Price
At the current price of about ₩1,336,000, post-spin total shares of about 46.29 million, and total market capitalization of about ₩62 trillion, the company is roughly a $40B name. The challenge in valuation is PE basis confusion after the spin-off:
PE-TTM is distorted by one-off gains from the spin-off: reported basis is about 35x, pulled down by one-time gains; continuing-operations basis is about 57x; data-provider basis is about 47-51x. The cleanest growth anchor is Samsung Securities' adjusted EPS series: 2025 ₩23,621 / 2026E ₩37,690 / 2027E ₩44,490, corresponding to forward PE of about 30-35x.
EV/EBITDA is about 22x, and PB is about 6-8x depending on basis: both are the richest among peers.
Three valuation ranges, intrinsic value per share in KRW:
Bear case [850,000, 1,100,000]: BIOSECURE benefit fails to materialize or is materially delayed, the biotech funding winter weighs on pipelines, growth normalizes, valuation compresses toward peers, meaning WuXi/Lonza EV/EBITDA of 14-18x, or the stock revisits the COVID peak around ₩1.03M.
Base case [1,250,000, 1,600,000]: quality premium holds, 30% growth execution continues, BIOSECURE is realized slowly, and forward PE is about 30-38x. The current price of ₩1,336,000 sits near the lower end of this range.
Bull case [1,900,000, 2,300,000]: BIOSECURE-driven order migration materially arrives, capacity ramps, and the stock is re-rated toward or above the broker consensus target price of ₩2,083,500.
The current price is at the lower end of the reasonable range, neither bubble-level expensive nor cheap enough to offer a safety margin. Upside requires BIOSECURE realization plus sustained high growth, with BIOSECURE still unproven. Downside risk comes from valuation compression and failed benefit realization. An ideal entry point would be a pullback to about below ₩1,150,000, corresponding to forward PE compressed to roughly 30x and EV/EBITDA moving toward 18x, while leaving a buffer for BIOSECURE uncertainty. At that point the rating could be raised to "Cautious Buy."
10. Risks, Focused on Permanent Capital Loss
High-valuation correction, the core risk: EV/EBITDA 22x, forward PE 30-35x, PB 6-8x. If any growth or catalyst expectation is disproven, there is meaningful room for valuation compression.
BIOSECURE falls short / U.S.-China tensions ease: the final enacted text did not name WuXi, and restrictions are delayed to 2027+; if 1260H does not include WuXi or geopolitics ease, the benefit disappears.
Major customer loss / order delays: customer concentration is high, and Samsung Securities says substantive order momentum may not recover until after the second half of 2026.
Capacity oversupply / heavy capex: 1.32 million liters of capacity plus massive investment; if demand slows, utilization and returns will face pressure. The industry already has concerns about overcapacity.
Biotech funding winter: upstream biotech financing contraction will transmit to CDMO demand.
KRW FX: revenue is in USD and reports are in KRW; won appreciation compresses reported revenue, while depreciation has the opposite effect.
Governance and Korea discount: Samsung affiliates hold about 74%, the free float is small, and the historical accounting controversy remains part of the background.
11. Catalysts and Tracking Indicators
Potential positive catalysts: BIOSECURE implementation rules are finalized and WuXi is included on 1260H; named large orders attributable to "WuXi order migration" appear; Plant 6/Bio Campus II comes online with high utilization; U.S. capacity at Rockville ramps; 2026 revenue reaches the upper end of 15-20% guidance.
Indicators to keep tracking:
Cumulative backlog and the customer composition of new signed orders, especially whether attributable order migration appears;
Quarterly revenue growth and operating margin, especially whether 45%+ can be maintained;
Capacity utilization and new-plant ramp;
Progress on BIOSECURE 1260H list / FAR amendments, with 2026-12 as the key time point;
WuXi Biologics orders and results, to see whether the benefit is zero-sum;
Broker consensus target prices and rating direction, especially whether Samsung Securities' cooling spreads;
KRW exchange rate;
Capex and free cash flow.
Re-rating signals: if material BIOSECURE-attributable order migration appears and orders accelerate, upgrade; if BIOSECURE fails plus growth normalizes plus valuation compresses, downgrade; if the share price pulls back below ₩1,150,000, upgrade the rating to Cautious Buy.
12. Zen Horizon Synthesis: A Top-Tier Outsourcing King, Expensive Because Its Quality Is Too Obvious
Combining the vertical view, from Samsung Group's wager to the snowballing build-out of the world's largest biologics manufacturing platform and the 2025 spin-off that removed the conflict-of-interest burden, with the horizontal view, where it has the largest capacity, highest gross margin, and fastest growth among peers but also the highest valuation, the profile of Samsung Biologics becomes clear: this is an almost flawless global top-tier CDMO, but the market already sees that excellence too clearly and prices it too fully.
12.1 Bull and Bear Reasons, All Traceable to Earlier Sections
Bull case: ① world-leading capacity and continuous expansion, with a very wide moat (Section 5); ② high growth plus 45% operating margin, with 2025 revenue up 30% and operating profit up 56.6% (Section 3); ③ spin-off removes conflict of interest and adds pure-play CDMO neutrality premium (Sections 2 and 5); ④ net BIOSECURE beneficiary, gaining relative to WuXi (Sections 6 and 7); ⑤ relationships with 17 of the top 20 pharmaceutical companies and backlog above $21.4 billion (Section 5).
Bear case: ① peer-high valuation, with EV/EBITDA of 22x, forward PE of 30-35x, and PB of 6-8x (Sections 7 and 9); ② BIOSECURE benefit is expectation-priced, low-realization, and delayed until 2027 (Section 6); ③ Samsung Securities recently cut its target price from ₩2.10 million to ₩1.80 million, a clear cooling signal (Section 8); ④ heavy-asset capex plus customer concentration plus biotech funding winter (Sections 3 and 10); ⑤ KRW FX plus governance discount (Section 10).
12.2 Pre-mortem: If This Investment Loses 40% Two Years From Now, the Most Likely Reason
The most likely scenario is valuation compression from overdrawn expectations and failed catalysts, rather than a deterioration in the company itself: BIOSECURE takes too long to implement, because WuXi is not added to 1260H or U.S.-China relations ease, and the market realizes that the "order migration" narrative is materializing far more slowly than expected. At the same time, the massive Bio Campus II capacity suffers insufficient utilization during a biotech funding winter, and growth normalizes from the 56% operating-profit growth rate. The market compresses Samsung from the sector-high 22x EV/EBITDA back toward Lonza/WuXi at 14-18x. Earnings do not collapse, yet the valuation is cut sharply. Samsung Securities' May 2026 downgrade is an early signal of this scenario.
12.3 Research Conclusion
Rating: Hold. Samsung Biologics is one of the world's best CDMOs, combining capacity dominance, 45% gross margin, 30% growth, post-spin purity, and BIOSECURE beneficiary status, almost every ingredient of a high-quality business. But that quality is already fully recognized and priced by the market. Its valuation is the most expensive among peers, while the BIOSECURE upside treated as the core catalyst is still mainly an expectation and has not yet appeared in order data. Even the most positive local brokers have recently cooled. The share price has pulled back about 33% from the 52-week high and euphoria has faded, yet EV/EBITDA of 22x and forward PE of 30-35x still lack a thick margin of safety. This is a company whose quality deserves a premium and whose current price requires waiting for a better entry point. The ideal buy point is a pullback to below ₩1,150,000, which would leave a buffer for BIOSECURE uncertainty and allow the rating to be raised to "Cautious Buy." Until then, hold the quality and track three lines closely: attributable BIOSECURE order migration, whether operating margin can defend 45%, and utilization during the capacity ramp.
13. Key Data Table
| Metric | Value (as of 2026-06-05 / latest reporting period, pure-play CDMO basis) |
|---|---|
| Current price / market cap | ~₩1,336,000 / ~₩62 trillion (roughly $40B; post-spin total shares about 46.29 million) |
| PE-TTM / forward PE (2026E) | ~47-51x (data providers; reported basis is depressed to ~35x by one-off spin-off gains) / ~30-35x |
| EV/EBITDA / PB | ~22x / ~6-8x (both the most expensive among peers) |
| 52-week range | About ₩1,300,000-1,987,000 (current price down about 33% from the high) |
| FY2025 revenue / operating profit (pure-play CDMO) | ₩4.557 trillion (+30.3% same basis) / ₩2.069 trillion (+56.6%) |
| FY2025 operating margin | About 45.4% (2024 restated: 37.8%) |
| 2026 Q1 revenue / operating profit | ₩1.257 trillion (+25.8%) / ₩580.8 billion (+35%), margin >46% |
| Capacity | Songdo about 785,000 liters (Plant 1-5) + U.S. 60,000 liters; 2032 target 1.32 million liters (world number one) |
| Backlog / customers | Cumulative >$21.4B; 17 of the world's top 20 pharmaceutical companies |
| Corporate structure | Spin-off in 2025-11; 207940 = pure-play CDMO; Bioepis belongs to Samsung Epis Holdings |
| Sell-side consensus target price | ~₩2,083,500 (20 firms, mainly Strong Buy); Samsung Securities recently cut to ₩1,800,000 |
| Rating / ideal buy point | Hold / upgrade to Cautious Buy on pullback below ₩1,150,000 |
Research Uncertainties, Known Gaps and Basis Differences
Two financial bases: from 2025 onward, the basis is pure-play CDMO, excluding Bioepis, and is not directly comparable with the consolidated basis for 2024 and earlier. This report uses the restated pure-play CDMO basis throughout, but some historical data have medium precision.
Large PE-TTM basis differences: reported basis at 35x, including one-off spin-off gains, versus continuing-operations basis at 57x, versus data providers at ~47-51x. This report uses forward PE of 30-35x as the main anchor and labels the cause.
USD market cap is heavily affected by exchange-rate timing: the won has been volatile in recent months, with KRW/USD around 1,360-1,530, putting USD market cap in the $40-46B range. This report uses KRW as the primary basis.
Specific customer concentration is undisclosed: the company does not publish single-customer shares. Estimates that the top five exceed half of revenue and a single customer can reach 20-30% are analytical-source inferences.
BIOSECURE realization is disputed: enactment establishes a positive, but WuXi has not been named, implementation starts no earlier than 2027, and order migration did not appear in 2025 data. Optimistic views, such as $30B of migration, and cautious views, such as broker cooling, both exist. This report judges it as "expectation pricing with low realization."
52-week low basis differs: different sources show ₩1,300,000 versus ₩982,000-992,000, mainly because of spin-off adjustment treatment. This report uses the post-spin basis of ₩1,300,000.
EODHD not used: EODHD data for this Korean stock are unreliable, with EOD returning sentinel values. Price, valuation, and history all use authoritative web sources, including company IR, stockanalysis, fnguide, Samsung Securities, and Korean financial media.
【Valuation Range】
- Bear case: ₩850,000 to ₩1,100,000
- Base case: ₩1,250,000 to ₩1,600,000
- Bull case: ₩1,900,000 to ₩2,300,000
【Ideal/Fair Buy Price】
- Ideal buy price: below ₩1,150,000
- Fair buy price reference: about ₩1,150,000
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free